All In Biotech

Drug Trial Radar · NCT06856772

Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial

Last checked: Nov 19, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 42,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

42,000

Planned (sponsor's estimate)

Start

Feb 28, 2025

Primary completion

Mar 28, 2028

Study completion Mar 28, 2028

Sponsor

Lead sponsor
Tor Biering-SørensenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Herlev and Gentofte Hospital
First posted
Mar 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Statins inhibit hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase which catalyzes the rate-limiting step in cholesterol synthesis. This in turn leads to reductions in concentrations of low-density lipoprotein (LDL) cholesterol and C-reactive protein which reduces the risk of incident atherosclerotic events among individuals both with and without a history of atherosclerotic cardiovascular Several pilot studies have suggested potential benefits of taking statin in the evening rather than in the morning. The primary objective of this study is to examine whether statin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking statin.

Conditions

  • Cardiovascular Diseases (CVD)
  • Drug Effect
  • Atherosclerosis Cardiovascular Disease

Interventions

  • Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)Drug

    Participants will be instructed to take their Statin daily at approx. 8PM-12AM.

  • Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)Drug

    Participants will be instructed to take their statin upon awakening/or with their breakfast (approx. 6AM-10AM).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of hospitalization for myocardial infarction, hospitalization for stroke or cardiovascular deathTime frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

    Hellerup, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.